Breaking News

GenCure Reports Successful First Run of 80L Bioreactor

Biomanufacturing CDMO says it’s among the first to harvest adult stem cells at large scale

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GenCure’s biomanufacturing services team has successfully completed a production run expanding and harvesting human mesenchymal stem cells (hMSCs) in an 80-liter bioreactor. GenCure, a subsidiary of BioBridge Global (BBG), announced a major expansion of its biomanufacturing facilities in February of this year.   The move to an 80-liter bioreactor addresses a critical need in the cell therapy industry for producing large-scale, consistent, clinical-grade adult stem cells needed to bring potential...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters